Compounds > 1,8-dihydroxy-3,7-dimethoxyxanthone
Page last updated: 2024-12-10
1,8-dihydroxy-3,7-dimethoxyxanthone
Description
1,8-dihydroxy-3,7-dimethoxyxanthone, also known as **mangiferin**, is a naturally occurring compound found in various plants, most notably the mango tree.
**Here's what makes it important for research:**
* **Pharmacological Activities:** Mangiferin has shown promising therapeutic potential across a wide range of medical fields.
* **Antioxidant:** It is a potent antioxidant, protecting cells from damage caused by free radicals.
* **Anti-inflammatory:** Mangiferin has anti-inflammatory properties that could be helpful in treating conditions like arthritis and inflammatory bowel disease.
* **Antidiabetic:** Studies suggest it may improve glucose tolerance and insulin sensitivity, potentially aiding in diabetes management.
* **Anti-cancer:** Mangiferin has shown some anticancer activity, inhibiting the growth and proliferation of cancer cells.
* **Neuroprotective:** It may protect the nervous system from damage and could have implications for treating neurological disorders like Alzheimer's and Parkinson's diseases.
* **Antiviral:** Mangiferin exhibits antiviral activity against some viruses, including the influenza virus.
* **Research Focus Areas:** Mangiferin's diverse pharmacological activities have made it a subject of intense research interest. Scientists are exploring its potential as:
* **Drug candidate:** Researchers are investigating how to utilize mangiferin in the development of new medications for a range of diseases.
* **Functional food ingredient:** Its antioxidant and anti-inflammatory properties make it attractive for use in functional foods and supplements.
* **Pharmaceutical excipient:** Mangiferin's potential as an excipient (a substance used to improve the formulation of medicines) is being explored.
**Challenges and Future Directions:**
While mangiferin shows promise, further research is needed to:
* **Understand its mechanism of action:** Researchers are working to clarify how mangiferin exerts its effects at the molecular level.
* **Improve its bioavailability:** Mangiferin's poor bioavailability (its ability to reach the bloodstream) is a challenge that needs to be overcome for it to be effectively used in medicine.
* **Develop safe and effective delivery systems:** Finding suitable ways to deliver mangiferin to target tissues is crucial for its therapeutic application.
In conclusion, 1,8-dihydroxy-3,7-dimethoxyxanthone (mangiferin) is a fascinating natural compound with a wide range of potential therapeutic applications. Ongoing research aims to unlock its full potential and translate its promising properties into effective treatments for various diseases.
1,8-dihydroxy-3,7-dimethoxyxanthone: isolated from Gentianopsis paludosa [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
2-O-methylswertianin : A member of the class of xanthones that is swertianin in which the hydroxy group at position 2 has been replaced by a methoxy group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Flora | Rank | Flora Definition | Family | Family Definition |
Gentianopsis | genus | [no description available] | Gentianaceae | A plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida.[MeSH] |
Gentianopsis paludosa | species | [no description available] | Gentianaceae | A plant family of the order Gentianales, subclass Asteridae, class Magnoliopsida.[MeSH] |
Cross-References
ID Source | ID |
PubMed CID | 5281653 |
CHEMBL ID | 3704820 |
CHEBI ID | 1228 |
SCHEMBL ID | 18240046 |
MeSH ID | M0485193 |
Synonyms (27)
Synonym |
2-o-methylswertianin |
1,8-dihydroxy-2,6-dimethoxyxanthone |
22172-17-4 |
methylswertianin |
swertiaperennin |
brn 1351740 |
9h-xanthen-9-one, 1,8-dihydroxy-2,6-dimethoxy- |
1,8-dihydroxy-2,6-dimethoxy-9h-xanthen-9-one |
xanthen-9-one, 1,8-dihydroxy-2,6-dimethoxy- |
1,8-dihydroxy-2,6-dimethoxyxanthen-9-one |
AKOS016013391 |
CHEMBL3704820 |
SCHEMBL18240046 |
1,8-dihydroxy-3,7-dimethoxyxanthone |
CHEBI:1228 |
AC-34321 |
Q-100281 |
1,8-dihydroxy-2,6-dimethoxy-xanthen-9-one |
FT-0698038 |
DTXSID50176709 |
us9114126, 2027ba2 |
bdbm174836 |
swertiaperrenin |
HY-N1995 |
Q27105429 |
CS-0018316 |
XAA17217 |
Roles (1)
Role | Description |
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
Class | Description |
xanthones | Any member of the class of xanthenes based on a xanthone skeleton. |
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
polyphenol | Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.35 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.30 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |